
- Industry news
Industry news
Trending now
- Category news
- Reports
Trending now
- Key trends
Trending now
- Multimedia
Multimedia
Trending now
- Journal
- Events
Trending now
- Suppliers
Suppliers
Trending now
- Home
- Industry news
Industry news
Trending now
- Category news
- Reports
Trending now
- Key trends
Trending now
- Multimedia
Multimedia
Trending now
- Events
Trending now
- Suppliers
Suppliers
Trending now
Naturex Granted Fraxinus-Based Patent to Combat Metabolic Syndrome By Improving Blood Sugar Regulation
Naturex announces the approval of U.S. Patent Number: 8,293,292 “Extract of Fraxinus Excelsior seeds and therapeutic applications thereof”.
28 Nov 2012 --- Naturex has developed FraxiPure, an innovative extract of Fraxinus with scientifically-documented properties supporting its use to fight the metabolic syndrome. Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular diseases and diabetes. According to the World Health Organization, 347 million people worldwide have diabetes. It also predicts that deaths associated with diabetes will increase by two thirds between 2008 and 2030. In the US, 7% of the population is affected by diabetes and it cost the United States an estimated $132 billion in 2002 in medical expenditures.








